What is it about?
Influenza virus and SARS-CoV-2 are typical examples of pandemic-prone and highly mutable viruses, making the development of broad-spectrum vaccines an urgent priority. We combined CXCL13 with circular RNA vaccine technology to develop a vaccine capable of inducing broad immune responses. This study shows the potential of CXCL13 to enhance the broad immune efficacy of vaccines and provides a new approach for the development of influenza and SARS-CoV-2 vaccines.
Featured Image
Photo by CDC on Unsplash
Why is it important?
We designed a general strategy to improve the magnitude and breadth of the antibody response induced by circular RNA vaccines and remodeled the immune microenvironment of lymph nodes by integrating CXCL13 and antigens into circular RNA for co-expression. The CXCL13 and antigen co-expression system induced robust cross-reactive antibody responses against multiple heterologous viral variants. These findings highlight the potential of CXCL13 as a novel vaccine adjuvant for inducing broad immune protection.
Perspectives
The impact of the COVID-19 pandemic has been immense, not only in terms of loss of life but also in its toll on the economy and personal freedoms. Influenza continues to remain active worldwide every year, and we are still at a loss on how to effectively combat it. I hope to provide a new perspective for the development of vaccines against both COVID-19 and influenza, enabling us to ultimately overcome these viruses.
Ling Zhao
Huazhong Agriculture University
Read the Original
This page is a summary of: CXCL13 promotes broad immune responses induced by circular RNA vaccines, Proceedings of the National Academy of Sciences, October 2024, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2406434121.
You can read the full text:
Contributors
The following have contributed to this page
